登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>A30L (MPXV) >A3L-M5243

Monkeypox virus (strain Zaire-96-I-16) A30L Protein, His Tag (MALS verified)

分子别名(Synonym)

A30L (MPXV)

表达区间及表达系统(Source)

Monkeypox virus (strain Zaire-96-I-16) A30L, His Tag (A3L-M5243) is expressed from human 293 cells (HEK293). It contains AA Ser 22 - Leu 146 (Accession # Q8V4U9-1).

Predicted N-terminus: His

Request for sequence

蛋白结构(Molecular Characterization)

A30L (MPXV) Structure

This protein carries a polyhistidine tag at the N-terminus.

The protein has a calculated MW of 16.0 kDa. The protein migrates as 25-35 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>90% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.

质量管理控制体系(QMS)

  1. 质量管理体系(ISO, GMP)
  2. 质量优势
  3. 质控流程
 

电泳(SDS-PAGE)

A30L (MPXV) SDS-PAGE

Monkeypox virus (strain Zaire-96-I-16) A30L, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

SEC-MALS

A30L (MPXV) SEC-MALS

The purity of Monkeypox virus (strain Zaire-96-I-16) A30L, His Tag (Cat. No. A3L-M5243) is more than 90% and the molecular weight of this protein is around 20-30 kDa verified by SEC-MALS.

Report

 

活性(Bioactivity)-ELISA

A30L (MPXV) ELISA

Immobilized Monkeypox virus (strain Zaire-96-I-16) A30L, His Tag (Cat. No. A3L-M5243) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-Monkeypox-A30L Antibody, Human IgG1 (5F3) with a linear range of 0.1-2 ng/mL (QC tested).

Protocol

 

活性(Bioactivity)-SPR

A30L (MPXV) SPR

Monoclonal Anti-Monkeypox-A30L Antibody, Human IgG1 (5F3) captured on Protein A Chip can bind Monkeypox virus (strain Zaire-96-I-16) A30L, His Tag (Cat. No. A3L-M5243) with an affinity constant of 0.601 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Protocol

 
评论(0)
 
ACRO质量管理体系
 
 

背景(Background)

Monkeypox is a rare zoonosis caused by monkeypox virus, which has become the most serious orthpoxvirus and consists of complex double stranded DNA. The cases are mostly in central and western Africa. The pathogenesis of monkeypox is that the virus invades the body from respiratory mucosa , multiplies in lymphocytes, and incurs into blood producing transient venereal toxemia. after the virus multiplies in cells, the cells can invade the blood and propagate to the skin of the whole body, causing lesions. A30L is a Envelope protein required for virus entry into host cell and for cell-cell fusion (syncytium formation).

 

前沿进展

Computer-Aided Multi-Epitope Based Vaccine Design Against Monkeypox Virus Surface Protein A30L: An Immunoinformatics Approach
Ramprasadh, Rajakumar, Srinivasan et al
Protein J (2023) 42 (6), 645-663
Abstract: Monkeypox, a viral zoonotic disease resembling smallpox, has emerged as a significant national epidemic primarily in Africa. Nevertheless, the recent global dissemination of this pathogen has engendered apprehension regarding its capacity to metamorphose into a sweeping pandemic. To effectively combat this menace, a multi-epitope vaccine has been meticulously engineered with the specific aim of targeting the cell envelope protein of Monkeypox virus (MPXV), thereby stimulating a potent immunological response while mitigating untoward effects. This new vaccine uses T-cell and B-cell epitopes from a highly antigenic, non-allergenic, non-toxic, conserved, and non-homologous A30L protein to provide protection against the virus. In order to ascertain the vaccine design with the utmost efficacy, protein-protein docking methodologies were employed to anticipate the intricate interactions with Toll-like receptors (TLR) 2, 3, 4, 6, and 8. This meticulous approach led the researchers to discern an optimal vaccine architecture, bolstered by affirmative prognostications derived from both molecular dynamics (MD) simulations and immune simulations. The current research findings indicate that the peptides ATHAAFEYSK, FFIVVATAAV, and MNSLSIFFV exhibited antigenic properties and were determined to be non-allergenic and non-toxic. Through the utilization of codon optimization and in-silico cloning techniques, our investigation revealed that the prospective vaccine exhibited a remarkable expression level within Escherichia coli. Moreover, upon conducting immune simulations, we observed the induction of a robust immune response characterized by elevated levels of both B-cell and T-cell mediated immunity. Moreover, as the initial prediction with in-silico techniques has yielded promising results these epitope-based vaccines can be recommended to in vitro and in silico studies to validate their immunogenic properties.© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Showing 1-1 of 1 papers.
Powered by BizGenius
 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定